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Background: Colorectal cancer (CRC) arises as a consequence of genetic events such as gene mutation and
epigenetic alteration. The aim of this study was to identify new hypermethylated candidate genes and methylation-
based therapeutic targets using vincristine in CRC.
Methods: We analyzed the methylation status of 27,578 CpG sites spanning more than 14,000 genes in CRC tissues
compared with adjacent normal tissues and normal colon tissues using Illumina bead chip array. Twenty-one
hypermethylated genes and 18 CpG island methylator phenotype markers were selected as candidate genes. The
methylation status of 39 genes was validated by quantitative methylation-specific polymerase chain reaction in CRC
tissues, adjacent normal tissues, normal colon cells, and three CRC cell lines. Of these, 29 hypermethylated candidate
genes were investigated using the demethylating effects of 5-aza-2′-deoxycytidine (5-aza-dC) and vincristine in CRC
cells.
Results: Thirty-two out of 39 genes were hypermethylated in CRC tissues compared with adjacent normal tissues.
Vincristine induced demethylation of methylated genes in CRC cells to the same extent as 5-aza-dC. The mRNA expression
of AKR1B1, CHST10, ELOVL4, FLI1, SOX5, STK33, and ZNF304 was restored by treatment with 5-aza-dC and vincristine.
Conclusion: These results suggest that these novel hypermethylated genes AKR1B1, CHST10, ELOVL4, SOX5, STK33, and
ZNF304 may be potential methylation biomarkers and therapeutic targets of vincristine in CRC.
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VincristineBackground
Colorectal cancer (CRC) is the third most common can-
cer and the second leading cause of cancer death in the
world. CRC is a consequence of genetic events including
gene mutations and epigenetic alterations that transform
colonic epithelial cells into adenocarcinoma cells [1].
The early detection of CRC is most important in cancer
patients to reduce cancer mortality [2]. Different stages
of CRC have different prognoses and the effects of adju-
vant chemotherapy differ between CRC stage II and* Correspondence: parksh@korea.ac.kr
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stated.stage III [3]. Current CRC chemotherapy consists of a
combination of cytotoxic DNA antimetabolites, such as
5-fluorouracil, leucovorin, or oxaliplatin. However, the
best combination of these anticancer drugs is still not
fully established [4]. To achieve this, epigenetic DNA
methylation was reported as a suitable approach for a
better understanding of CRC progression and thera-
peutic targets [5].
A great number of studies have focused on the epigen-
etic alterations of tumor suppressor genes in the regula-
tion of cancer initiation and progression [6]. Gene-specific
methylation changes in promoter CpG regions have been
largely related to biological processes of tumor progres-
sion including cell proliferation, communication, adhe-
sion, mobility, signal transduction, and drug resistance [7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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> 65 4 13 5
≤ 65 6 8 5
Gender
Male 2 14 5
Female 8 7 5
Location
Rectum 5 5
Right, left colon 10 16 5
Clinical stage
I + II 11 5







Maximum tumor diameter (mm)
> 25 7 5




Alcohol intake (3 times/week)
Yes 11 4
No 10 6
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exon 1 regions of tumor suppressor genes has been corre-
lated with transcriptional silencing of downstream genes
in colorectal cancer [8,9]. Many genes silenced by aberrant
methylation, including CDKN2A, THBS, and SFRP, have
been proposed to be associated with CRC tumorigenesis
[10-13]. Moreover, promoter methylation was also re-
ferred to as the CpG island methylator phenotype (CIMP)
[14,15]. CIMP-positive CRC was distinguished from
CIMP-negative CRC patients by clinicopathological fac-
tors [16], and CIMP was associated with development of
the serrated pathway of CRC [17]. Clinically, several CIMPs
containingMLH1 (a mismatch repair gene), and microsat-
ellite instability were characterized to be associated with
CRC prognosis [18,19]. Furthermore, a panel of CIMP in-
cluding RUNX3, CACNA1G, IGF2, and MLH1 consists of
specific markers for clinical trials [20]. Hughes et al.
reviewed the existing literature of 640 potential relevant
papers to summarize CIMPs in CRC [21]. Although there
are many lines of evidence that have been proposed as po-
tential biomarkers for CRC in humans, many researchers
continue to research new CRC-specific methylation mark-
ers. Recently, methylation chip array techniques have been
widely used to identify new DNA methylation biomarkers
in CRC. However, array data are needed to confirm other
methods such as quantitative methylation polymerase chain
reaction (PCR) (QMSP), methylation-sensitive high-resolution
melting, and pyrosequencing [22-24]. QMSP is a sensitive
tool and offers quantitative analysis of DNA methylation
status [25].
Vincristine is a vinca alkaloid from the plant Cathar-
anthus roseus, and mainly arrests mitosis in metaphase
by binding to tubulin dimers [26]. It is used as a chemo-
therapy drug for various types of cancers, including
non-Hodgkin’s lymphoma [27], acute lymphoblastic leu-
kemia, lung cancer, breast cancer, and CRC [28-31]. Re-
cently, cyclophosphamide, vincristine, and prednisone
(COP) chemotherapy was used to significantly improve
overall survival and progression-free survival in primary
colonic lymphoma patients [32]. There was one report
that low concentration of vincristine reduced the meth-
ylated cytosine in human lung adenocarcinoma cells
[33]. However, the DNA methylating-based effects of
vincristine are still unknown for methylation marker
genes in CRC.
In this study, to identify new hypermethylated candi-
date genes in CRC patients, we analyzed methylation
profiles using bead chip array-based technology and
QMSP. In addition, to identify methylation-based thera-
peutic target genes, the demethylating effect of vincris-
tine was examined using 21 hypermethylated candidate
genes and 18 CIMP markers. Correlations between meth-
ylation status and mRNA expression were analyzed by
reverse-transcription PCR.Methods
Tissues
Thirty-one pairs of colorectal cancer (CRC) tissues and
adjacent normal tissues and 10 normal colon tissues
were obtained from the Department of Colorectal Sur-
gery, Korea University Medical Center. The characteris-
tics of each subject are summarized in Table 1. This
study was approved by the institutional review board of
Korea University and informed consent was obtained
(IRB No. KU-IRB-10-08-A-1). The diagnosis of CRC tis-
sues was acquired from pathology reports, the institu-
tional review board, and histological evaluations. Fresh
tissue samples were frozen in liquid nitrogen after resec-
tion and stored at −80°C.
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One normal colon cell line (CCD18Co) and three CRC
cell lines (SW480, Dukes’ type B; DLD-1, Dukes’ type C;
LoVo, Dukes’ type C and stage IV) were obtained from
the American Type Culture Collection (Manassas, VA,
USA). CCD18Co cells were cultured in Eagle’s minimum
essential medium and the three CRC cells were cultured
in RPMI 1640 medium, all supplemented with 10% fetal
bovine serum (Hyclone, Logan, UT, USA) and 1% peni-
cillin/streptomycin (P/S; Invitrogen), and maintained at
37°C and 5% CO2 atmosphere.
Genomic DNA extraction
Genomic DNA was extracted using the QIAamp DNA
Mini-Kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s recommendations. Tissue samples were
ground up by 3-mm diameter punches and then mixed
with 700 μL lysis buffer containing 20 μg/mL Labo Pass
protease K (Cosmo Gene Tech., Seoul, Korea), 20 mM
Tris∙HCl (pH 8.0), 5 mM EDTA (pH 8.0), 400 mM NaCl,
and 1% SDS solution (Sigma-Aldrich, St. Louis, MO,
USA). The mixed samples were incubated at 42°C
overnight. After incubation, genomic DNA was purified
by phenol/chloroform extraction. Genomic DNA was
eluted in 100 μL of water and quantified with a Nano-
Drop ND-100 device (Thermo Fisher Scientific, Hudson,
NH, USA).
Sodium bisulfite DNA modification
Two micrograms of genomic DNA in a volume of 20 μL
RNase-free water was bisulfite-converted using the Epi-
Tect fast DNA bisulfite kit (Qiagen). Bisulfite conversion
was performed according to the manufacturer’s recom-
mendations. The reaction was performed by mixing
85 μL bisulfite mix solution and 35 μL DNA protect buf-
fer in 200 μL PCR tubes at room temperature. The
bisulfite-converted genomic DNA was eluted from the
column with 100 μL dH2O and stored at −80°C until
use.
Methylation bead chip array
Human Methylation 27 DNA Analysis Bead Chip (Illumina
Inc., San Diego, CA, USA) is a methylation-profiling tech-
nology based on bisulfite modification of DNA. This bead
chip array can provide methylation information at a
single-base resolution for 27,578 CpG sites spanning more
than 14,000 genes. One microgram of bisulfite-converted
genomic DNA was applied to the bead chips using
Illumina-supplied reagents and conditions. After exten-
sion, the array was fluorescently stained and scanned, and
the intensities of the M (methylated) and U (unmethy-
lated) bead types were measured. Each methylation data
point is represented by fluorescent signals from the M and
U alleles. The ratio of fluorescent signals was thencomputed from the two alleles; β value = (max (M, 0))/
(|U| + |M| + 100). The β value reflects the methylation
level of each CpG site. A β value of 0–1.0 indicates the
percent methylation from 0% to 100%, respectively.
Quantitative methylation-specific PCR (QMSP)
Quantitative methylation status in the bisulfite-converted
genomic DNA was confirmed by quantitative real-time
PCR using the 7000 HT Real-Time PCR System (Applied
Biosystems) according to the manufacturer’s recommen-
dations. Methylation primers for 21 candidate genes and
18 CIMP markers were designed using the MethPrimer
software (http://www.urogene.org/methprimer/). Primers
for QMSP were designed for large promoter CpG islands
containing detected CpG sites near the transcription start
site (Additional file 1: Table S1). PCR reactions were per-
formed using an optical 96-well tray in a final volume of
20 μL. The reaction mixture consisted of 5 μL 2X Maxima
SYBR Green/ROX qPCR master mix (Thermo Fisher Sci-
entific), 250 nM of each primer, and 30 ng of bisulfite-
converted DNA template. The QMSP program was as
follows: 50°C for 2 min and 95°C for 10 min, followed by
45 cycles at 95°C for 15 s, and then 60°C for 1 min. After
PCR, a thermal melt profile was performed to examine
the homogeneity of the PCR application. Each DNA sam-
ple was analyzed in duplicate, and the mean quantity was
used for further analysis. Relative quantification of the
amplified gene levels in the bisulfite-converted genomic
DNA sample was performed by measuring the threshold
cycle (CT) values of target genes and β-actin (ACTB). The
mean quantity of genes was divided by the mean quantity
of ACTB and was used for the normalization of input
DNA. The negative values for ACTB were excluded from
the methylation analysis. The bisulfite-converted genomic
DNA of a known concentration was drawn at 1, 1/4, 1/16,
and 1/64 via serial dilutions, and then used in a standard
curve for quantification. The modified genomic DNA by
CpG methyltransferase M.SssI (NEB, Ipswich, MA, USA)
was used as a positive control according to the manufac-
turer’s recommendations. DNA methylation according to
M.SssI was verified using the restriction enzyme BstUI
(NEB).
Reverse-transcription PCR
mRNA was extracted using the commercial RNeasy
Mini-kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendations. The mRNA was eluted
in 20 μL of DEPC water (Qiagen) and quantified with a
NanoDrop ND-100 device (Thermo Fisher Scientific).
One microgram of mRNA from each sample was sub-
jected to cDNA synthesis using Maloney murine leukemia
virus RT and random hexamers (Promega, Madison, WI,
USA). cDNA synthesis was performed according to the
manufacturer’s recommendations by mixing 1 μL of 1 μg
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10 mM dNTP, 0.5 μL RNasein, 1 μL M-MLV reverse tran-
scriptase, and 11.5 μL dH2O in PCR tubes. The mixture
was then incubated at 37°C for 1 h. cDNA was diluted
with 20 μL dH2O and stored at −80°C until use. Primers
were designed using primer3 version 0.4.0 (http://primer3.
ut.ee/) and are shown in Additional file 1: Table S2. cDNA
was amplified by PCR with primers for each target gene.
The RT-PCR program was as follows: 95°C for 10 min,
followed by 35 cycles at 95°C for 15 s, 60°C for 15 s, and
then at 72°C for 45 s. ACTB was amplified simultaneously
with the other PCR products and was used as a control
for RNA integrity.
Chemical treatment
To determine the optimal concentration of 5-aza-2′-
deoxycytidine (5-aza-dC) and vincristine (Sigma-Aldrich)
in CRC cell lines, we measured cell viability with the
MTT assay (Additional file 2: Figure S1) according to the
manufacturer’s recommendations using MTT reagents
(10 μL/well, 7.5 mg/mL in phosphate-buffered saline) and
dimethyl sulfoxide (50 μL/well, Sigma-Aldrich). To iden-
tify the demethylating effect of treatment with anticancer
drugs, CCD18Co, SW480, DLD-1, and LoVo cells were
seeded in six-well culture plates (SPL LifeSscience,
Pocheon, Korea) at a density of 0.5 × 105 cells per well.
After 24 h, cells were cultured in serum-free media con-
taining either 30 μM 5-aza-dC or 100 nM vincristine in
10 μL dimethyl sulfoxide for 48 h at 37°C in a 5% CO2 at-
mosphere. After 48 h, cells were washed in PBS (Sigma-
Aldrich) three times and then harvested.Figure 1 Hypermethylation of promoter CpG sites for 21 genes by m
promoter CpG islands for 21 genes were identified using methylation chip
normal tissues. All genes were significantly strongly hypermethylated in the
normal tissues and normal tissues (P < 0.05). N: normal colon tissues, T: CRCStatistical analysis
The statistical significance of the methylation bead chip
array data was determined using a paired t-test based on
Δβ means (means of β value in CRC tissues – means of
β value in normal tissues). The methylated intensity ratio
in CRC was confirmed by fold-change (methylated inten-
sity ratio of CRC tissues/methylated intensity ratio of nor-
mal colon tissues) and odds ratio (methylated intensity
ratio contract of unmethylated intensity in CRC). The false
discovery rate (FDR) was controlled by adjusting the P
value using the Benjamini-Hochberg algorithm, the incor-
rectly substituted probabilities of specifically observed
methylation CpG sites for each gene in P values. The
methylated intensity ratio of QMSP was determined by the
percentage of methylated reference (PMR) gene, and the
PMR value was defined as [(GENE)sample/(ACTB)sample]/
[(GENE)M.SssI/(ACTB)M.SssI] × 100. The significance of dif-
ferent PMR values among CRC tissues and adjacent nor-
mal tissues was defined with the chi-squared test and
analysis of variance test using Sigma Stat (SPSS Inc.,
Chicago, IL, USA). All statistical tests were two-sided and
P values of < 0.05 were considered to indicate statistical
significance.
Results
Selection of 21 hypermethylated candidate genes in CRC
To identify the aberrant methylation of various genes in
CRC, we performed a methylation chip array in 10 normal
colon tissues, and 21 CRC tissues and adjacent normal
tissues. We found a total of 3,177 CpG sites in the pro-
moter regions (1,704 CpG sites, 53.6%) and non-promoterethylation chip array. The methylation statuses of CpG sites in
array in 10 normal colon tissues, 21 CRC tissues, and 21 adjacent
ir promoter CpG islands in CRC tissues compared with adjacent
tissues, AN: adjacent normal tissues.
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CpG sites identified in CRC tissues compared with adja-
cent normal and normal colon tissues, according to statis-
tical significance determined by the paired t-test and an
FDR P value of <0.001 based on a Δβ mean of 0.1. Among
3,177 CpG sites, we identified 597 genes with hyper-
methylated CpG sites in promoter CpG islands (data not
shown). Finally, we selected 21 candidate genes that con-
tained strongly hypermethylated CpG sites in promoter
CpG islands in CRC tissues compared with adjacent nor-
mal tissues (Figure 1).Candidate genesA
B Candidate genes
Figure 2 Validation of methylation status of 21 candidate genes and
18 CIMP markers was validated using QMSP in 10 CRC tissues compared w
lines (B). Methylated intensity ratio of QMSP data was determined by the
tissues and adjacent normal tissues was defined with the analysis of varian
indicate statistical significance. * indicates the methylation status of genes
significant.Validation of 39 genes by QMSP
To confirm the methylation status of 21 candidate genes
from the array results and 18 CIMP markers, we vali-
dated the methylation status in the promoter CpG
islands of selected genes by QMSP in 10 different CRC
tissues compared with adjacent normal tissue. The quan-
titative analysis with the PMR value supported the differ-
ential methylation status between CRC and normal
tissues. The methylation status in the promoter CpG
islands of all candidate genes was frequently higher in
CRC tissues compared with adjacent normal tissues exceptCIMP markers
CIMP markers
18 CIMP markers. The methylation status of 21 candidate genes and
ith adjacent normal tissues (A), normal colon cells, and three CRC cell
PMR values. The significance of different methylation statuses in CRC
ce test using Sigma Stat. Values of P < 0.05 were considered to
in CRC compared with adjacent normal tissues was not statistically
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markers, namely, ADAMTS1, CHFR, IGF2, IGFBP3, NEU-
ROG1, SFRP1,WRN, CRABP1,MGMT, RASSF1A, RUNX3,
and SFRP2 was also frequently higher in CRC tissues
compared with adjacent normal tissues (Figure 2A). In
normal colon cells, SLC8A3, ZNF272, IGF2, APC,
MGMT, and CDKN2A were methylated. All genes were
hypermethylated in one or more CRC cell lines except
WRN (Figure 2B).
Demethylation effect of vincristine on 29
hypermethylated genes in CRC cell lines
The 10 genes hypermethylated in normal colon cells or
not significantly hypermethylated in tumor tissue were
excluded for chemical treatment. Eighteen candidate
genes and 11 CIMP markers were selected to identify
the demethylating effects of vincristine. The methylation




Figure 3 Demethylating effect of 5-aza-dC and vincristine on methyla
of hypermethylated genes in normal colon cells (A) and CRC cells (B) were id
tine for 48 h at 37°C. Methylated intensity ratio was determined by the percennormal colon cells, most genes were not affected by 5-
aza-dC and vincristine treatment (Figure 3A). In con-
trast, 14 candidate genes and seven CIMP markers were
significantly demethylated by 5-aza-dC treatment in two
CRC cell lines (Figure 3B). In addition, 12 candidate
genes (ADHFE1, AKR1B1, CHST10, ELOVL4, EYA4,
FLI1, QKI, STK33, SOX5, UNC5C, and ZNF304) and
eight CIMP markers (ADAMTS1, CHFR, CRABP1, NEU-
ROG1, RUNX3, SFRP1, THBD, and TAC1) were signifi-
cantly demethylated by vincristine treatment in two
more CRC cell lines (Figure 3B).
Restoration of mRNA expression by vincristine in DLD-1
cells
The effect of methylation on mRNA expression was in-
vestigated by MSP and RT-PCR analysis in 5-aza-dC-
and vincristine-treated DLD-1 and CCD18Co cells. The






ted genes in three CRC cell lines. Changes in the methylation status
entified by QMSP after treatment with 30 μM 5-aza-dC or 100 nM vincris-
tage of methylated reference (PMR).
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with 5-aza-dC and vincristine in DLD-1 cells, but were
not changed in CCD18Co cells. The methylation status
of CHST10, ELOVL4, EYA4, and ZNF304 was highly de-
creased by vincristine (Figure 4A). The mRNA expres-
sion of AKR1B1, CHST10, ELOVL4, FLI1, STK33, SOX5,
and ZNF304 was increased by treatment with 5-aza-dC
and vincristine in DLD-1 cells, but EYA4 mRNA expres-
sion was not detected. The mRNA expression levels of
all genes were not affected by 5-aza-dC treatment in
CCD18Co cells (Figure 4B). The methylation of AKR1B1
was not decreased significantly by treatment with 5-aza-
dC or vincristine, but the mRNA expression levels of
this gene were increased (Figure 4). These results sug-
gest that vincristine promotes the demethylation of
CHST10, ELOVL4, FLI1, SOX5, STK33, and ZNF304,
and the methylation-mediated silencing or down expres-
sion of these genes was restored by vincristine in DLD-1
cells to the same extent as 5-aza-dC, as measured by
mRNA expression.
Discussion
This study identified novel hypermethylated genes in CRC
through a genome-wide study. DNA hypermethylation
leads to the downregulation and silencing of tumor sup-
pressor genes during the pathogenesis of various human
cancers [10,34-36]. Recently, genome-wide array-based
studies have reported altered DNA methylation gene pro-
files in CRC [22-24]. Oster et al. identified hypermethy-
lated FLI1, ST6GALNAC5, TWIST1, ADHFE1, JAM2,
IRF4, CNRIP1, NRG1, and EYA4 genes in the adenomas











Figure 4 Association between DNA methylation and mRNA expressio
status (A) and mRNA expression (B) of eight genes, including six newly ident
CCD18Co and DLD-1 cells following 30 μM 5-aza-dC or 100 nM vincristine tre
other PCR products and was used as a control for DNA methylation and mRNreported 20 top-ranking hypermethylated genes in CRC
[23]. Mori et al. identified several novel candidate CRC
biomarkers including VSX2, BEND4, NPTX1, BTG4, and
GLP1R [24]. In our methylation chip array results, we dis-
covered 1,411 hypermethylation CpG sites that were lo-
cated in the promoter CpG islands of 597 genes (data not
shown), and selected 21 candidate genes for further study
(Figure 1). Several candidate genes were consistent with
previous reports, such as BTG4, FLI1, TWIST1, ADHFE1,
UNC5C, and SPG20 [22-24]. We validated the methyla-
tion status in the promoter CpG islands of candidate
genes by QMSP for the investigation of large contiguous
CpG sites, the results of which were concordant with the
array results for most genes except FLI1 (Figure 2A).
Among the various CIMP markers in CRC, 18 CIMP
markers were selected for the validation of methylation
status and methylation-based therapeutic targets in
CRC. ADAMTS1, CHFR, DAPK1, IGF2, IGFBP3, NEU-
ROG1, SFRP1, TAC1, THBD, and WRN were also hyper-
methylated in our chip data (data not shown). In our
QMSP results of CIMP markers, DAPK1, TAC1, THBD,
APC, CACNA1G, and CDKN2A were not significantly
methylated in CRC tissues (Figure 2A). These discrepan-
cies may be due to differences in the epigenomes of tu-
mors or patient ethnic background.
The hypermethylation of AKR1B1, CHST10, ELOVL4,
SOX5, STK33, and ZNF304 have not been previously
reported in CRC. AKR1B1, aldo-keto reductase family 1,
member B1, catalyzes the reduction of aldehydes including
the aldehyde form of glucose. It was reported to be down-
regulated in endometrial cancer and gastric cancer [37,38].











n of eight genes in CCD18Co and DLD-1. The DNA methylation
ified hypermethylated genes, was measured using QMSP and RT-PCR in
atment for 48 h at 37°C. ACTB was amplified simultaneously with the
A integrity. Marker: molecular weight DNA marker.
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[39]. ELOVL4 gene product, elongation of very long
chain fatty acids 4, is responsible for the biosynthesis of
fatty acids [40]. Hypermethylation of ELOVL4 was re-
ported in hepatocellular carcinoma and pancreatic
adenocarcinoma by genome-wide methylation analysis
[41,42]. SOX5 is a member of the SOX (SRY-related
HMG-box) family of transcription factors. It is well
known that SOX5 regulates embryonic development and
determines cell fate [43]. STK33, serine-threonine kinase
33, is located on chromosome 11p15.3, a gene-rich re-
gion that has been associated with human diseases and
malignancies [44]. ZNF304, zinc finger protein 304, com-
bines two conserved domains, class II AU-rich elements
and a Krüppel-associated box, and is associated with the
regulation of lymphocyte activation [45].
DNA methylation-mediated silencing of gene expres-
sion can be restored by demethylation agents such as 5-
aza-dC. DNA methyltransferase inhibitor, 5′-azacytidine,
may act as an inducer of cell differentiation by causing
de-methylation and re-expression of genes silenced by
hypermethylation [46]. 5-Azacytidine was approved in
2004 by the US Food and Drug Administration for treat-
ing myelodysplastic syndrome [47], and 5-aza-dC as a 5-
azacytidine analog was widely used in DNA methylation
studies [48]. Vincristine is a microtubule inhibitor and is
commonly used for chemotherapy in pediatric acute
lymphoblastic patients [32]. Several anticancer drugs are
associated with drug-induced DNA hypermethylation in
human lung adenocarcinoma and rhabdomyosarcoma
cells [33]. Interestingly, the methylated cytosine was re-
duced after treatment with concentration of vincristine
less than 100 μmole but it was induced after treatment
with higher than 1000 μmole in human lung adenocar-
cinoma cells [33]. In this study, we selected 100 nM as
an optimal concentration of vincristine which does not
effect on the viability of CRC cells using MTT assay.
Vincristine induced demethylation of methylated genes
in CRC cells to the same extent as 5-aza-dC. In addition,
vincristine restored the mRNA expression of CHST10,
ELOVL4, FLI1, STK33, SOX5, and ZNF304 in CRC cells.
Interestingly, the methylation status of AKR1B1 was not
affected, but its mRNA expression was increased by both
drugs. It may be regulated by upstream genes, with a
demethylating effect by both drugs. Our results provide
insights into the potential functional impact of vincris-
tine on methylated genes in CRC.
Conclusions
This study has identified novel candidate genes, AKR1B1,
CHST10, ELOVL4, SOX5, STK33, and ZNF304, and
provided evidence for their suitability as methylation bio-
markers of CRC. We also analyzed the DNA methylation-
based therapeutic effects of vincristine in CRC.Additional files
Additional file 1: Table S1. Primers for Quantitative methylation
specific PCR (QMSP). Table S2. Primers for mRNA expression.
Additional file 2: Figure S1. Cell viability of CCD18Co, SW480, DLD-1,
and LoVo cells by 5-aza-dC and vincristine. Cell viability of four cell lines
after treatment with various concentrations of 5-aza-dC and vincristine
for three days was evaluated by MTT assay. The cell viability of four cell
lines was significantly reduced after treatment with concentration of
5-aza-dC greater than 30 μM (A) and did not change significantly after
treatment with concentrations of vincristine less than 100 nM for two or
three days (B). *p-Values of <0.05 were considered statistically significant.
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NRG1: Neuregulin 1; QKI: Quaking homolog, KH domain RNA binding;
QMSP: Quantitative methylation-specific polymerase chain reaction;
PMR: Percentage of methylated reference; RASSF1A: Ras association domain-
containing protein 1; RT-PCR: Reverse transcription polymerase chain
reaction; RUNX3: Runt-related transcription factor 3; SLC8A3: Solute carrier
family 8, member 3; SFRP1: Secreted frizzled-related protein 1;
SFRP2: Secreted frizzled-related protein 1; SOX5: SPY(sex determining region
Y)-box 5; SPG20: Spastic paraplegia 20; STK33: Serine-threonine kinase 33;
ST6GALNAC5: ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5; TAC1: Protachykinin-1;
THBD: Thrombomodulin; THBS: Thrombospondin; TWIST1: Twist-related
protein 1; UNC5C: Unc-5 homolog C; VSX2: Visual system homeobox 2;
WRN: Werner syndrome; ZNF272: Zinc finger protein 272; ZNF304: Zinc finger
protein 304; 5-aza-dC: 5-aza-2′-deoxycytidine.
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